|
|
|
| Effect of solinacine combined with pelvic floor biofeedback for treating women with severe overactive bladder |
| Suining Central Hospital, Sichuan Province, 629000 |
|
|
|
|
Abstract To explore the efficacy of solinacine combined with pelvic floor biofeedback for treating women with severe overactive bladder (OAB). Methods: A total of 86 women with severe OAB were selected as the research subjects from February 2016 to February 2021. According to the personal wishes of the women, these women were divided into group A (47 cases given solinacine combined with pelvic floor biofeedback treatment) and group B (39 cases given solinacin treatment). The changes of score evaluated by pelvic floor muscle strength assessment (MOS), bladder hyperactivity symptom score (OABSS), and King health questionnaire (KHQ) of the women in the two groups were compared between before and after treatment. Results: The scores of each item and total items of OABSS of the women in the two groups in 1 month and 3 months after treatment had decreased significantly, and which of the women in group A were significantly lower than those of the women in group B (P<0.05). The score of MOS of the women in the two groups in 1 month and 3 months after treatment had increased significantly, and which of the women in group A were significantly higher than those of the women in group B (P<0.05). The score of KHQ of the women in the two groups in 1 month and 3 months after treatment had decreased significantly (P<0.05). The score of KHQ of the women in the two groups in 1 month after treatment had no significant different from that before treatment (P>0.05), which of the women in group A in 3 months after treatment was significantly lower than that of the women in group B (P<0.05). There was no significant difference in the incidence of adverse reactions (8.5% vs. 7.7%) of the women between the two groups (P>0.05). Conclusion: Solinacine combined with pelvic floor biofeedback for treating women with severe OAB can further alleviate their clinical symptoms without increasing their adverse reactions.
|
|
|
|
|
|
|
|
|
